Aardvark Therapeutics, Inc. (AARD) · Oct 23, 2026 · Other events

Aardvark lifts ARD-101 hold, but HERO efficacy stays exploratory

Clinical hold lifted — FDA hold lifted; HERO stopped early before planned enrollment

Aardvark’s FDA clinical hold is lifted for ARD-101, reopening the PWS program—but early-stopped HERO data offers only an exploratory efficacy signal.

Aardvark is a clinical-stage biotech building ARD-101 as an oral treatment for hyperphagia in Prader-Willi syndrome, with broader metabolic-disease ambitions. The company had been navigating a full FDA clinical hold after pausing its Phase 3 program over cardiac findings at high doses.

The regulatory block is cleared, but the pivotal program is not back on a normal track. The filing says the FDA lifted the clinical hold, which removes the immediate regulatory stop and keeps ARD-101’s development path open. 〔0〕 But the HERO and open-label studies were already terminated early, enrollment was truncated, and the filing explicitly says the results should be considered exploratory. 〔1〕 This is a meaningful recovery from the hold, not a clean clinical win.

The efficacy signal is encouraging in direction but too incomplete to establish proof. The company reports a modest reduction in hyperphagia scores versus placebo, faster improvement by Week 2, additional improvement when placebo patients switched to ARD-101, and rebound after treatment stopped. 〔2〕 Those patterns support a possible drug effect, but the early termination leaves limited Week 12 data and no properly powered final efficacy test.

MeasureFiling resultComparison / limitation
HERO randomized designARD-101 n=45; placebo n=45 plannedTrial stopped early; 67 participants enrolled overall (HERO design / Executive Summary)
Baseline HERO HQ-CTARD-101 22.5; placebo 22.8Roughly balanced starting severity (HERO Scores)
Cardiac safety3 of 31 high-dose healthy volunteers had QRS increases >25%Findings were reversible; no QRS prolongation at 200 mg or 400 mg BID (Cardiac Safety)
HERO treatment-emergent AEs52% ARD-101; 50% placeboMostly mild to moderate (Safety Summary)
Serious cardiac eventOne Grade 4 polymorphic ventricular tachycardia eventOccurred at 800 mg BID with concurrent pitolisant (Safety Summary)

The safety story is improved at therapeutic exposures, but not erased. The follow-up studies found no QRS prolongation at the intended 200 mg BID dose or the 400 mg BID supratherapeutic dose, and no QTc increases in healthy volunteers. 〔3〕 That addresses the specific signal that triggered the hold, while the prior Grade 4 cardiac event and the CYP2D6 interaction with pitolisant remain important constraints for future trial design and patient selection.

Bottom line: Lifting the hold preserves ARD-101’s development option and removes the immediate regulatory overhang, but the truncated HERO dataset is not strong enough to validate efficacy. The story moves from “blocked” to “back in play, with a redesigned or additional clinical path still to prove.”

What to watch next

Webcast reviewing HERO/OLE data, October 23

Original filing on SEC EDGAR

More Aardvark Therapeutics, Inc. news

Aardvark lifts ARD-101 hold, but HERO efficacy stays exploratory | AARD Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.